Biogen (BIIB) stock soars following positive Alzheimer’s drug trial. Salim Syed discusses this as Mizuho upgraded BIIB to buy from neutral and raised its price target to $270 from $207. He talks about how this new drug is likely to receive regulatory approval.He then goes over expectations for biopharmaceutical stocks. Tune in to find out more about the stock market today.
28 Sep 2022
Market On Close
14 Dec 2022
The Watch List
31 Jan 2023
Morning Trade Live
23 Jan 2023
The Watch List
14 Nov 2022
The Watch List
09 Dec 2022